AbbVie Inc. - notizie pubblicate 394 - letture 16.044
ABBVIE INC.
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
Corporate news june 14, 2024 abbvie recommends shareholders reject tutanota's "mini-tender" offer open a printable version of this page email the url of this page to a fr ...
ABBVIE INC.
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
Immunology r&d news june 13, 2024 abbvie and futuregen announce license agreement to develop next-generation therapy for inflammatory bowel disease open a printable version of ...
ABBVIE INC.
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor Alpha (FRα) Expressing Platinum Sensitive Ovarian Cancer
Oncology r&d news june 06, 2024 abbvie announces positive topline results from phase 2 piccolo trial evaluating mirvetuximab soravtansine (elahere®) for high folate receptor-a ...
ABBVIE INC.
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
Oncology r&d news june 05, 2024 abbvie advances oncology pipeline with start of multiple myeloma phase 3 clinical trial for investigational asset abbv-383 open a printable vers ...
ABBVIE INC.
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
Immunology june 04, 2024 rinvoq® (upadacitinib) now available for pediatric patients two years and older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis o ...
ABBVIE INC.
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Corporate news june 03, 2024 abbvie to present at the goldman sachs 45th annual global healthcare conference open a printable version of this page email the url of this page to a f ...
ABBVIE INC.
Specialized Disclosure Report - Form SD
Exhibit 1.01 abbvie inc. conflict minerals report for the year ended december 31, 2023 as adopted by the securities and exchange commission (sec) pursuant to the dodd-frank wall st ...
ABBVIE INC.
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Immunology r&d news may 31, 2024 abbvie receives positive chmp opinion for risankizumab (skyrizi®) for the treatment of adults with moderately to severely active ulcerative co ...
ABBVIE INC.
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
R&d news may 28, 2024 abbvie showcases robust solid tumor pipeline at asco 2024 with new data from its innovative antibody-drug conjugate (adc) platform open a printable versio ...
ABBVIE INC.
AbbVie Completes Acquisition of Landos Biopharma
R&d news may 23, 2024 abbvie completes acquisition of landos biopharma open a printable version of this page email the url of this page to a friend - adds first-in-class invest ...
ABBVIE INC.
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
Immunology r&d news may 17, 2024 abbvie presents new data supporting leading gastroenterology portfolio at 2024 digestive disease week® open a printable version of this page e ...
ABBVIE INC.
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Corporate news r&d news may 13, 2024 abbvie and gilgamesh pharmaceuticals announce collaboration and option-to-license agreement to develop next-generation therapies for psychi ...
ABBVIE INC.
Amendment to Current Report - Form 8-K/A
United states securities and exchange commission washington, d.c. 20549 form 8-k/a (amendment no. 1) current report pursuant to section 13 or 15(d) of the securities exchange act o ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ABBVIE INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti